Intensified preoperative treatment improved 3-year disease-free survival by 8.8 points

In a 458-patient randomised trial of high-risk locally advanced rectal cancer, a chemotherapy-intensified total neoadjuvant therapy regimen produced higher 3-year disease-free survival than conventional chemoradiotherapy. It also caused substantially more grade 3 or worse toxicity before surgery.

The study at a glance

Study design	Multicenter, randomised, phase III trial.
Who took part	458 people with stage II or III rectal cancer and at least one high-risk feature.
What was tested	Doublet-LC total neoadjuvant therapy, with capecitabine plus oxaliplatin before, during and after long-course radiotherapy, versus conventional capecitabine-based chemoradiotherapy before surgery followed by adjuvant chemotherapy.
What was measured	Disease-free survival, the time after treatment without recurrence or death.

The trial tested a more intensive preoperative approach

This was a multicenter randomised phase III trial in 458 people with stage II or III rectal cancer considered at high risk of recurrence elsewhere in the body. Random assignment is the study design best able to test whether one treatment strategy causes a difference in outcomes, because it aims to balance known and unknown patient characteristics between groups.

To enter, patients needed at least one high-risk feature on staging. These included a tumour extending into nearby structures, extensive lymph-node involvement, tumour close to the mesorectal fascia, which is the tissue plane surgeons use around the rectum, or signs that cancer had entered blood vessels outside the bowel wall.

The 232 patients assigned to the experimental group received total neoadjuvant therapy, meaning all planned chemotherapy and radiotherapy were delivered before surgery. Their regimen used capecitabine and oxaliplatin, a two-drug or “doublet” chemotherapy combination, before radiotherapy, during long-course radiotherapy, and afterwards. The 226 patients in the comparison group received capecitabine with the same type of radiotherapy before surgery, then planned chemotherapy after surgery.

The primary outcome was disease-free survival, which counts the time until cancer returns, spreads, or the patient dies. The trial team followed patients for a median of 51 months. This was a selected high-risk population, so its results should be applied with care to people whose rectal cancer has different staging features.

Disease-free and metastasis-free survival were higher

At three years, disease-free survival was 74.8% with the intensified total neoadjuvant regimen and 66.0% with conventional chemoradiotherapy. That is an absolute difference of 8.8 percentage points. The hazard ratio was 0.674, with a 95% confidence interval from 0.489 to 0.929. A hazard ratio below 1 favours the experimental treatment; this interval indicates that the observed result was statistically compatible with a lower risk of a disease-free survival event in the experimental group.

Metastasis-free survival, meaning survival without cancer spreading to distant organs, was also higher: 77.7% versus 67.6%, with a hazard ratio of 0.655 (95% CI, 0.469 to 0.915). This fits the study’s rationale. For this group of patients, distant recurrence is a major concern, and the experimental strategy delivered more systemic chemotherapy, treatment intended to reach cancer cells beyond the pelvis, before surgery.

The pathologic complete response rate was 26.37% with the intensified regimen, compared with 9.80% in the conventional group. A pathologic complete response means the pathologist found no remaining viable cancer in the surgical specimen after preoperative treatment. It is an encouraging treatment-response measure, but it is not the same outcome as living longer or remaining free of recurrence.

Local or regional failure was uncommon in both groups, at 6.03% and 6.19%, respectively. The abstract does not report overall survival results, so this paper does not establish whether the strategy changes how long patients live overall.

The added chemotherapy came with more severe toxicity before surgery

The benefit in disease control has to be read alongside the treatment burden. During the neoadjuvant phase, before surgery, 27.59% of patients receiving doublet-LC total neoadjuvant therapy had a grade 3 or worse adverse event, compared with 8.56% receiving conventional chemoradiotherapy. Grade 3 or higher events are severe according to the trial’s standard toxicity grading system and may require medical intervention, treatment delays, or hospital care.

Across the entire treatment course, severe adverse events were reported in 28.02% of the experimental group and 24.32% of the comparison group. The difference was not statistically significant in this trial. Major postoperative complications were also similar, 3.98% versus 2.94%.

Those later comparisons should not obscure the earlier toxicity difference. Moving chemotherapy from after surgery to before surgery can improve the chance that patients receive planned systemic treatment, but it concentrates treatment intensity into the preoperative period. For a person already managing symptoms from a low rectal tumour, bowel function, weight loss, nerve symptoms, kidney function, and day-to-day reserve may all affect whether an oxaliplatin-containing regimen is tolerable.

The paper describes toxicity as manageable. That word means the investigators were able to deliver the regimen within the trial setting. It does not mean that severe side effects are minor, predictable for every patient, or acceptable to every patient facing treatment choices.

Where these results fit, and where caution remains

This trial provides strong evidence that, among patients matching its high-risk eligibility criteria, the tested intensified preoperative strategy caused better three-year disease-free and metastasis-free survival than the conventional sequence used in the comparison arm. The results support total neoadjuvant therapy as an option within modern rectal-cancer care, while also showing that the precise regimen and sequence affect toxicity.

It does not show that every form of total neoadjuvant therapy performs the same way. The authors call for comparisons with short-course radiotherapy approaches and with regimens that do not give doublet chemotherapy concurrently with radiotherapy. Those comparisons matter because many total neoadjuvant therapy schedules are already in use, with different balances of convenience, chemotherapy exposure, tumour response, and side effects.

I would also avoid treating the 26.37% pathologic complete response rate as a reason to assume organ preservation is available from this study. Everyone in the trial was treated before surgery in a protocol built around surgery. The abstract provides no non-operative management outcomes, no quality-of-life results, and no detail on whether response changed the type of surgery performed.

For patients with high-risk locally advanced rectal cancer, the useful conversation is likely to be about fit: whether the staging features, treatment goals, medical condition, and tolerance for added preoperative toxicity resemble the people and circumstances studied here.